What’s new
OCB present ToxNav on ESMO-GI 2018
ESMO World Congress on Gastrointestinal Cancer Barcelona, Spain 20-23 Jun 2018 At ESMO-GI on 22nd June 2018 OCB was pleased
MBM and OCB launch ColoProg in China on March 7th 2018
Oxford developed prognostic assay for risk of post-surgical recurrence in Stage II colorectal cancer patients to be available throughout China
Oxford Cancer Biomarkers appoints David Browning as its Chief Executive Officer and Board member
Oxford, UK, 9th October 2017 Oxford Cancer Biomarkers has appointed healthcare industry leader David Browning as Chief Executive Officer and
MBM and OCB announce the set-up of joint laboratories in Ningbo Meishan and Oxford at the 3rd China Medical Devices Int’l Summit on 26th August 2017
Oxford, UK, 1st September 2017 The announcement, at the 3rd China Medical Devices Int’l Summit, follows the signing in March
Oxford Cancer Biomarkers welcomes major investment partnership with MGMED, Inc.
Investment will drive rapid uptake of OCB’s cancer tests and expand its development pipeline Oxford Cancer Biomarkers Ltd (OCB), the
Oxford Cancer Biomarkers announces strategic collaboration with My-BioMed Biotechnology Co. Ltd
Collaboration will allow OCB’s suite of precision oncology In Vitro Diagnostic tests to be rolled out across the People’s Republic
Chemotherapy side effect predicting Oxford biotech firm secures CE marking
Oxford Cancer Biomarker’s ColoTox test will now be available to UK patients considering chemotherapy Oxford, UK, 14th March 2017 –
Oxford Cancer Biomarkers announces ColoTox test for predicting cancer chemotherapy toxicity enters clinical studies
First patient enrolled in clinical utility study Oxford, UK, 9th November 2016 Oxford Cancer Biomarkers Ltd (OCB), the UK-based company